Timing of sodium–glucose cotransporter 2 inhibitor initiation and post‐discharge outcomes in acute heart failure with diabetes: A population‐based cohort study

Results from randomized trials suggest benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure. We aim to examine the real-world effectiveness of early versus delayed post-discharge SGLT2 inhibitor initiation in people with acute heart failure and type 2 diabetes.